药物重定位是治疗冠状病毒 COVID-19 的一种替代方法。
Drug repositioning is an alternative for the treatment of coronavirus COVID-19.
机构信息
Universidade Federal de Santa Maria, Programa de Pós-graduacão em Ciências Farmacêuticas, Santa Maria, RS, Brasil.
Universidade Federal de Santa Maria, Pós-Graduação Mestrado Profissional em Ciências da Saúde.
出版信息
Int J Antimicrob Agents. 2020 Jun;55(6):105969. doi: 10.1016/j.ijantimicag.2020.105969. Epub 2020 Apr 9.
Abstract
Given the extreme importance of the current pandemic caused by COVID-19, and as scientists agree there is no identified pharmacological treatment, where possible, therapeutic alternatives are raised through drug repositioning. This paper presents a selection of studies involving drugs from different pharmaceutical classes with activity against SARS-CoV-2 and SARS-CoV, with the potential for use in the treatment of COVID-19 disease.
摘要
鉴于由 COVID-19 引起的当前大流行的极端重要性，并且由于科学家们一致认为目前尚无确定的药理学治疗方法，因此在可能的情况下，通过药物重定位来提出治疗的替代方法。本文介绍了涉及对 SARS-CoV-2 和 SARS-CoV 具有活性的不同药物类别的药物的一系列研究，这些药物具有治疗 COVID-19 疾病的潜力。
相似文献
1
Drug repositioning is an alternative for the treatment of coronavirus COVID-19.
Int J Antimicrob Agents. 2020 Jun;55(6):105969. doi: 10.1016/j.ijantimicag.2020.105969. Epub 2020 Apr 9.
2
Repurposing antimalarials and other drugs for COVID-19.
Travel Med Infect Dis. 2020 Mar-Apr;34:101658. doi: 10.1016/j.tmaid.2020.101658. Epub 2020 Apr 2.
3
Is hydroxychloroquine beneficial for COVID-19 patients?
Cell Death Dis. 2020 Jul 8;11(7):512. doi: 10.1038/s41419-020-2721-8.
4
Race to find COVID-19 treatments accelerates.
Science. 2020 Mar 27;367(6485):1412-1413. doi: 10.1126/science.367.6485.1412.
5
Arguments in favour of remdesivir for treating SARS-CoV-2 infections.
Int J Antimicrob Agents. 2020 Apr;55(4):105933. doi: 10.1016/j.ijantimicag.2020.105933. Epub 2020 Mar 6.
6
Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review.
Rev Med Virol. 2020 Sep;30(5):e2136. doi: 10.1002/rmv.2136. Epub 2020 Jul 9.
7
Treatment options for COVID-19: The reality and challenges.
J Microbiol Immunol Infect. 2020 Jun;53(3):436-443. doi: 10.1016/j.jmii.2020.03.034. Epub 2020 Apr 4.
8
A Case of Breakthrough COVID-19 during Hydroxychloroquine Maintenance.
J Korean Med Sci. 2020 Jun 22;35(24):e231. doi: 10.3346/jkms.2020.35.e231.
9
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.
JAMA. 2020 May 12;323(18):1824-1836. doi: 10.1001/jama.2020.6019.
10
Some drugs for COVID-19.
Med Lett Drugs Ther. 2020 Apr 6;62(1595):49-50.
引用本文的文献
1
Biodegradation of Chloroquine by a Fungus from Amazonian Soil, CBMAI 2758.
J Fungi (Basel). 2025 Aug 4;11(8):579. doi: 10.3390/jof11080579.
2
Endolysosome-targeted nanoparticle delivery of antiviral therapy for coronavirus infections.
Life Sci Alliance. 2025 Feb 3;8(4). doi: 10.26508/lsa.202403182. Print 2025 Apr.
3
How does a extract influence the components of isolated rotavirus particles from stool samples collected in a clinical setting from children?
Saudi J Biol Sci. 2024 Aug;31(8):104031. doi: 10.1016/j.sjbs.2024.104031. Epub 2024 May 26.
4
Discovery of common molecular signatures and drug repurposing for COVID-19/Asthma comorbidity: ACE2 and multi-partite networks.
Cell Cycle. 2024 Feb;23(4):405-434. doi: 10.1080/15384101.2024.2340859. Epub 2024 Apr 19.
5
Drug Repurposing: A Leading Strategy for New Threats and Targets.
ACS Pharmacol Transl Sci. 2024 Apr 1;7(4):915-932. doi: 10.1021/acsptsci.3c00361. eCollection 2024 Apr 12.
6
Safety Evaluation and Population Pharmacokinetics of Camostat Mesylate and Its Major Metabolites Using a Phase I Study.
Pharmaceutics. 2023 Sep 21;15(9):2357. doi: 10.3390/pharmaceutics15092357.
7
Assessment of the proarrhythmic effects of repurposed antimalarials for COVID-19 treatment using a comprehensive proarrhythmia assay (CiPA).
Front Pharmacol. 2023 Aug 15;14:1220796. doi: 10.3389/fphar.2023.1220796. eCollection 2023.
8
Can Probiotics, Particularly UCO-979C and UCO-25A, Be Preventive Alternatives against SARS-CoV-2?
Biology (Basel). 2023 Feb 28;12(3):384. doi: 10.3390/biology12030384.
9
Detection of Adverse Drug Reactions in COVID-19 Hospitalized Patients in Saudi Arabia: A Retrospective Study by ADR Prompt Indicators.
Healthcare (Basel). 2023 Feb 23;11(5):660. doi: 10.3390/healthcare11050660.
10
The curse and blessing of abundance-the evolution of drug interaction databases and their impact on drug network analysis.
Gigascience. 2022 Dec 28;12(1). doi: 10.1093/gigascience/giad011. Epub 2023 Mar 9.
本文引用的文献
1
Erratum to ``A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence'' [International Journal of Antimicrobial Agents 55/6 (2020) 105948].
Int J Antimicrob Agents. 2020 Sep;56(3):106137. doi: 10.1016/j.ijantimicag.2020.106137. Epub 2020 Aug 18.
2
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
Nature. 2020 Jul;583(7816):459-468. doi: 10.1038/s41586-020-2286-9. Epub 2020 Apr 30.
3
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
4
Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro.
Cell Discov. 2020 Mar 18;6:16. doi: 10.1038/s41421-020-0156-0. eCollection 2020.
5
Teicoplanin: an alternative drug for the treatment of COVID-19?
Int J Antimicrob Agents. 2020 Apr;55(4):105944. doi: 10.1016/j.ijantimicag.2020.105944. Epub 2020 Mar 13.
6
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Clin Infect Dis. 2020 Jul 28;71(15):732-739. doi: 10.1093/cid/ciaa237.
7
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
Biosci Trends. 2020 Mar 16;14(1):72-73. doi: 10.5582/bst.2020.01047. Epub 2020 Feb 19.
8
[Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia].
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Feb 16;43(0):E014. doi: 10.3760/cma.j.issn.1001-0939.2020.0014.
9
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Cell Res. 2020 Mar;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4.
10
Drug repositioning, a new alternative in infectious diseases.
Braz J Infect Dis. 2018 May-Jun;22(3):252-256. doi: 10.1016/j.bjid.2018.05.007. Epub 2018 Jun 28.
Zotero 插件